Navigation Links
Popular osteoporosis drugs triple risk of bone necrosis
Date:1/15/2008

A University of British Columbia and Vancouver Coastal Health Research Institute study has found that a popular class of osteoporosis drugs nearly triples the risk of developing bone necrosis, a condition that can lead to disfigurement and incapacitating pain.

The research is the largest study of bone necrosis and bisphosphonates, a class of drugs used by millions of women worldwide to help prevent bone fractures due to osteoporosis. It is also the first study to explore the link between bone necrosis and specific brands of bisphosphonates, such as Actonel, Didrocal and Fosamax. Researchers found that all three brands had similar outcomes.

Bone necrosis, a relatively rare disease diagnosed in approximately 1 in 20,000 people per year, leads to permanent loss of blood supply to the bones. Without adequate blood supply, the bone tissue dies and causes the bone to collapse. The disease primarily affects shoulders, knees and hips at the joints, causing severe pain and immobility.

Published online by the Journal of Rheumatology today, the findings follow a recent U.S. Food and Drug Administration alert about bisphosphonates that highlighted the possibility of severe and sometimes incapacitating bone, joint and/or muscle pain in patients taking the drugs. (To view the FDA alert, visit: http://www.fda.gov/cder/drug/infopage/bisphosphonates/default.htm.)

According to the American Dental Association, more than 190 million prescriptions have been written for bisphosphonates worldwide. The drugs are promoted in direct-to-consumer advertisements on U.S. television stations.

The message for women taking these medications is to pay attention to your pain, said principal investigator Dr. Mahyar Etminan of the Centre for Clinical Epidemiology and Evaluation at UBC and VCHRI. Given the widespread use of these drugs, it is important that women and their doctors know the risks that come with taking them.

Etminan cautions that bisphosphonate use may increase in the future as the possible link between estrogen use and breast cancer prompts women to switch from estrogen therapy to bisphosphonate therapy to prevent osteoporotic bone fractures. Another reason may be the availability of new bisphosphonates that come in once-a-month or once-a-year doses.

The epidemiological study, a collaboration between UBC, VCHRI and McGill University, is based on the health records of 88,000 Quebec residents from 1996 to 2003. The team undertook the research after academic papers began linking necrosis of the jaw with the use of bisphosphonates.

This is particularly important work, said Dr. John Esdaile, professor and head, Rheumatology, UBC and scientific director, Arthritis Research Centre of Canada located at VCHRI's Centre for Hip Health.

Although the osteonecrosis side-effect is rare, the use of the bisphosphonates is very common, Esdaile adds. People taking bisphosphonates are now hearing about the potential side-effects, and this study result will permit physicians to better inform them what the order of magnitude of the risk may be.


'/>"/>

Contact: Basil Waugh
basil.waugh@ubc.ca
604-822-2048
University of British Columbia
Source:Eurekalert

Related medicine news :

1. Climate change, gender differences, health among EurekAlert! 10 Most Popular Stories in 2007
2. Will Lipodissolve Continue to Remain Popular?
3. One-Third of Popular Songs Refer to Substance Abuse
4. Giant Eagle Expands Popular Generic Prescription Program and Now Offers 400 for $4
5. Banco Popular Commits To Make A Difference Day 2007
6. Study Rates Heart Health of Popular Diet Plans
7. HSA Plans Gain Popularity as Premium Costs Rise
8. Oral osteoporosis meds appear to reduce the risk of jaw degradation
9. Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
10. Many Osteoporosis Medications Prevent Fractures, But None Is Proven Best
11. High-trauma fractures in older men and women linked to osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... 2017 , ... The Pennsylvania Athletic Trainers’ Society’s (PATS) Annual ... Convention Center on June 8-10. The weekend consisted of many educational presentations, ... scholarship presentations, and professional networking. , On Friday June 9th, PATS hosted ...
(Date:6/23/2017)... ... 2017 , ... The Rhode Island Quality Institute (RIQI) and ... Dashboards, an innovative new service enabling healthcare providers to proactively coordinate care and ... Dashboards provide near real-time data about patients admitted to and/or discharged from acute ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or from ... how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, ... symptoms of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when ... read it, and some people don't like it at all. FindaTopDoc took a look ... , Erotic literature can give readers a taste of their deepest, darkest fantasies and ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State ... 18 to 20. , The two-day conference is focused on advancing scientific knowledge ... improving patients’ lives and eliminating racial breast cancer-related disparities. The conference theme is ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 8, 2017  StatLab Medical Products ("StatLab" ... manufacturer of diagnostic supplies for the anatomic ... & Company LP ("Cressey & Company"), a ... growth-focused investment in the Company. Cressey & ... from selling shareholder, Prairie Capital, L.P., with ...
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
(Date:6/5/2017)... , June 5, 2017 The ... brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded ... Cincinnati Enquirer . Results are based on an ... in organizational health and workplace improvement. The survey measures several ... ...
Breaking Medicine Technology: